Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
XZP-3621 + esomeprazole
- Development stage
- Unknown
- Lead developer
- Xuanzhu Biopharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
XZP-3621 + esomeprazole is a combination of two drugs: XZP-3621, an orally administered small molecule dual inhibitor of anaplastic lymphoma kinase (ALK) and ROS proto-oncogene 1 receptor tyrosine kinase (ROS1), and esomeprazole, a proton pump inhibitor. XZP‑3621 is being developed by Xuanzhu Biopharmaceutical for the treatment of non-small cell lung cancer (NSCLC) and other cancers driven by ALK or ROS1 alterations. Esomeprazole is used to reduce gastric acid secretion and may be co-administered to manage gastrointestinal side effects or drug-drug interactions affecting absorption. The combination has been studied in healthy volunteers to assess pharmacokinetic interactions and safety[2][3][6][8].
- Brand names
- Nexium
- Other names
- EsomeprazoleNexiumXZP 3621XZP3621XZP-3621
02
Targets
ROS1 (Proto-oncogene tyrosine-protein kinase ROS)ALK (Anaplastic lymphoma kinase receptor tyrosine kinase)ATP4A (Potassium–transporting ATPase alpha chain 1)
Beyond the preview
Go deeper on XZP-3621 + esomeprazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on XZP-3621 + esomeprazole.